Global Clinical Knowledge Graphs for Genomics Market 2026: Microsoft, IBM, Illumina, and Genomenon Scale AI and Cloud to Drive 20.7 Percent CAGR Growth
Yahoo Finance ·
The worldwide market for clinical knowledge graphs in genomics is experiencing rapid development, expanding from 1.46 billion dollars in 2025 to 1.76 billion dollars in 2026 at a compound annual growth rate of 20.4 percent. Furthermore, the sector is projected to hit 3.74 billion dollars by 2030, advancing at a compound annual growth rate of 20.7 percent. Industry leaders such as Microsoft, IBM, Illumina, and Genomenon are actively scaling cloud-based artificial intelligence, variant interpretation systems, and genomic data integration to boost precision medicine and drug discovery. Key growth drivers include rising demand for targeted therapies and advanced analytics. Notably, Genomenon introduced its artificial intelligence-driven knowledgebase platform, the Genomenon Genomic Graph, in December 2024 to enhance clinical decision-making and biomarker research.
AI 시장 분석
The global genomics clinical knowledge graph market is projected to grow from $1.46 billion in 2025 to $1.76 billion in 2026, registering a compound annual growth rate of 20.4%. Investments in related technologies are surging due to the accelerated adoption of AI and cloud-based precision medicine solutions by major players such as Microsoft and IBM. Investors should focus on the structural growth of the healthcare sector driven by genomic data integration and accelerated drug discovery.
상승 영향
- Biotech — The genomics knowledge graph market is recording a high CAGR of 20.7%, maximizing the efficiency of precision medicine and drug discovery.
- AI — Major companies like Microsoft and IBM are adopting cloud-based AI genomic variant interpretation platforms, increasing related software sales.
DYAX 전담 분석
The genomics clinical knowledge graph market is expected to grow at a CAGR of 20.7% to reach $3.74 billion by 2030. Increased demand for AI-based analytics, cloud platforms, and precision medicine acts as a core growth driver, pulling earnings improvements for related companies.
In the bullish scenario, expanded approvals of personalized therapeutics and accelerated healthcare IT investments take place, while in the bearish scenario, tightened data security regulations and technology adoption delays may act as risks. Key metrics to watch are the compound annual growth rate (CAGR) and the number of FDA personalized medicine approvals.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 51% · Bearish (Short) 49%
418 participants
Related News
- Alphabet Loses $482B in Market Value as AI Spending Surges
- Analysis Behind the Sharp Decline in Medical Prop Tr Shares
- B Riley Highlights Key AdTech Stocks to Watch Ahead of Q3 Earnings
- Mobile Virtualization Market Report 2026: Valuation Projected to Hit US$21 Billion by 2032
- Teva Stock Doubles in a Year: What to Expect Over the Next Three Years
- Reasons Behind Sandisk's Recent Stock Plunge
